Adma Biologics (ADMA) Research & Development (2011 - 2026)
Adma Biologics' (ADMA) quarterly Research & Development came in at $1.4 million in Q4 2025, up 251.92% YoY from $391000.0 in Q4 2024, and down 9.95% on a QoQ basis from $1.5 million in Q3 2025.
Adma Biologics (ADMA) Research & Development (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 13 years of Research & Development data on file, last reported at $1.4 million in Q4 2025.
- Quarterly Research & Development rose 251.92% year-over-year to $1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.8 million (up 162.6% YoY) and the FY2025 annual result came in at $4.8 million, up 162.66% from the prior year.
- Research & Development fell to $1.4 million in Q4 2025, from $1.5 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $1.5 million in Q3 2025 to a low of $391000.0 in Q4 2024.
- A 5-year average of $856700.0 and a median of $840500.0 in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development sank 60.09% — and 2025, when it soared 270.87%.
- Tracing ADMA's Research & Development over 5 years: stood at $728928.0 in 2021, then jumped by 47.42% to $1.1 million in 2022, then tumbled by 58.49% to $446000.0 in 2023, then declined by 12.33% to $391000.0 in 2024, then jumped by 251.92% to $1.4 million in 2025.
- The last three Research & Development figures came in at $1.4 million (Q4 2025), $1.5 million (Q3 2025), and $1.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 6.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.01 Mn |
| Dec 31, 2025 | 1.38 Mn |
| Sep 30, 2025 | 1.53 Mn |
| Jun 30, 2025 | 1.03 Mn |
| Mar 31, 2025 | 826,000.00 |
| Dec 31, 2024 | 391,000.00 |
| Sep 30, 2024 | 412,000.00 |
| Jun 30, 2024 | 560,000.00 |
| Mar 31, 2024 | 450,000.00 |
| Dec 31, 2023 | 446,000.00 |
| Sep 30, 2023 | 596,000.00 |
| Jun 30, 2023 | 1.40 Mn |
| Mar 31, 2023 | 855,000.00 |
| Dec 31, 2022 | 1.07 Mn |
| Sep 30, 2022 | 1.04 Mn |
| Jun 30, 2022 | 873,386.00 |
| Mar 31, 2022 | 624,111.00 |
| Dec 31, 2021 | 728,928.00 |
| Sep 30, 2021 | 770,557.00 |
| Jun 30, 2021 | 1.16 Mn |